Fadia Tohmé Shaya

Learn More
STATEMENT OF PROBLEM AND RATIONALE The management of chronic conditions, such as overactive bladder (OAB), is often limited by lack of patient adherence to medication. This article compares persistence rates among Medicaid patients who were prescribed 1 of 3 drugs for treatment of OAB: 2 long-acting agents with once-daily dosing, tolterodine tartrate(More)
BACKGROUND Asthma and COPD can significantly affect patients and pose a substantial economic burden for both patients and managed-care plans. This study compares utilization outcomes in patients with asthma, COPD, or co-occurring asthma and COPD in a Medicaid population, and assesses the incremental burden of COPD in patients with asthma. METHODS We(More)
Background and Aims Non-adherence to 5-aminosalicylic acid (5-ASA) is associated with adverse outcomes; however, no data exist regarding cost and non-adherence. Our aim was to determine the association between adherence to maintenance therapy and healthcare costs. Methods Patients in the Maryland CareFirst BlueCross BlueShield program with a follow-up of(More)
The purpose of this study is to examine the incremental economic burden of sleep apnea syndrome (SAS) among individuals with concomitant asthma, chronic obstructive pulmonary disease (COPD), or both (i.e., asthma/COPD). Maryland Medicaid claims data were used to identify beneficiaries with asthma (n = 3,072), COPD (n = 3,455), or both (n = 2,604). We(More)
STUDY OBJECTIVE To compare persistence, switching, and discontinuation rates among patients taking brand-name selective serotonin reuptake inhibitors (SSRIs). DESIGN Retrospective cohort study. Data Source. Protocare Sciences managed care database. PATIENTS A total of 14,933 patients with depression, posttraumatic stress disorder, or social anxiety(More)
INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a respiratory illness that has a major impact on health care expenditures in the U.S.1,2 It is associated with a high morbidity rate and creates a deep economic burden on patients, health care providers, and society in general.3 Ten million physician visits and more than two million(More)
OBJECTIVE To identify predictors of compliance with antihypertensive combination therapy in a Medicaid population. METHODS Retrospective medical and pharmacy claims data for Maryland Medicaid patients receiving angiotensin converting enzyme inhibitors (ACEls)/hydrochlorothiazides (HCTZs) or ACEl/calcium channel blockers as fixed-dose combinations or(More)
BACKGROUND Medicaid covers a high-risk population typically underrepresented in clinical trial data and largely absent in observational studies of real-world cardiovascular risks associated with thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, which are used to manage type 2 diabetes. In November 2013, the FDA removed prescribing(More)
OBJECTIVES To characterize a comprehensive comorbidity profile and to explore the economic implications of comorbidity among patients with chronic obstructive pulmonary disease (COPD). METHODS This retrospective cohort study analyzed medical claims from the Maryland Medicaid database. We employed a 1:2 case-control design to select COPD patients (n=1388)(More)
BACKGROUND The differential effects of selective cyclooxygenase-2 (COX-2) inhibitors compared with nonspecific nonsteroidal anti-inflammatory agents (NSAIDs) on platelet aggregation and prostacyclin/thromboxane balance have led to concerns that COX-2 inhibitors may increase the risk for cardiovascular thrombotic events. Empirical studies have generally been(More)